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Abstract 
Objectives: Fluorodeoxyglucose(FDG)-positron emission tomography/contrast enhanced- 
computed tomography (PET/CE-CT) involving whole-body scanning first by non-CE-CT and 
FDG-PET, followed by CE-CT has been used for detailed examination of pancreatic lesions. We 
evaluated PET/CE-CT images with regard to differential diagnosis, staging, treatment response, 
and postoperative recurrence in pancreatic cancer. 
Methods: PET/CE-CT was conducted in 108 patients with pancreatic cancer and 41 patients 
with other pancreatic tumor diseases.  
Results: The maximum standardized uptake value (SUVmax) overlapped in benign and malignant 
cases, suggesting that differential diagnosis of pancreatic tumors based on the SUVmax is difficult. 
In the evaluation of staging in 31 resectable pancreatic cancer by PET/CE-CT, the diagnostic 
accuracy rate was more than 80% for most factors concerning local invasion and 94% for distant 
metastasis, but only 42% for lymph node metastasis. Significant positive correlations were found 
between the SUVmax and tumor size/markers, suggesting that SUVmax may be a useful indicator 
for the treatment response. Regarding the diagnosis of the postoperative recurrence, PET/CE-CT 
correctly detected local recurrence in all the 11 cases of recurrence, while abdominal CE-CT 
detected only 7 out of 11 cases, suggesting that PET/CE-CT is superior in this context. 
 Conclusions: PET/CE-CT is useful for the clinical management of pancreatic cancer. 
 
Keywords: contrast-enhanced PET/CT (PET/CE-CT), differential diagnosis, clinical management, 
pancreatic cancer  
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Introduction 
Despite recent significant advances in cancer diagnosis and treatment, pancreatic cancer 
patients still have a very poor prognosis [1]. In Japan, the number of pancreatic cancer patients in 
2002 was 21,386, while the number of pancreatic cancer-related deaths in 2006 was 23,366 [2], 
indicating that the number of patients with pancreatic cancer was almost equal to the number of 
pancreatic cancer-related deaths. However, a slight improvement in survival has been observed 
with the introduction of gemcitabine (GEM) and S-1 as chemotherapeutic medications for 
pancreatic cancer [3, 4]. Given this situation, clinical practice guidelines for pancreatic cancer 
have recently been established in Japan, and treatment regimens are determined on the basis of 
the extent of pancreatic cancer, which is evaluated by imaging. Contrast-enhanced-abdominal CT 
(abdominal CE-CT) has primarily been used to determine the extent of pancreatic cancer [5]. 
However, imaging diagnosis is also essential in the postoperative monitoring of pancreatic 
cancers, which often recur soon after surgery; abdominal CE-CT imaging has also been used for 
this purpose. 
Positron emission tomography (PET), a new imaging modality, has recently been introduced in 
daily clinical practice, but functional imaging by PET alone does not have much diagnostic 
significance [6]. Acquisition of consecutive PET and CT (PET/CT) images in addition to 
combination of functional PET and anatomical CT images dramatically enhances the usefulness 
of PET as an imaging modality [7]. We have been using PET/CT (Aquiduo16; Toshiba) since the 
introduction of this technique at the Shikoku Cancer Center in April 2006; the CT apparatus has 
been dedicated to dynamic studies (contrast-enhanced PET/CT [PET/CE-CT]) on the 
development of this technique as a key imaging modality in the diagnosis and follow-up 
examinations of patients with pancreatic cancer. In this study, we retrospectively compared 
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PET/CE-CT and abdominal CE-CT, which has been used as the primary imaging modality for the 
diagnosis and management of pancreatic cancer, and evaluated the efficacy of these modalities 
for the following functions: differential diagnosis of benign and malignant pancreatic lesions, 
evaluation of the extent of invasive pancreatic ductal cancer, assessment of treatment effects, and 
diagnosis of postoperative recurrence. 
 
Material and Methods 
Subjects 
PET/CE-CT imaging technology was used to determine the extent of invasive pancreatic ductal 
cancer in 108 patients (64 men and 44 women, ages 45–86 years). The extent of cancer was 
determined according to Classification of Pancreatic Carcinoma 5th Edition (edited by the Japan 
Pancreas Society) [8]. Among the 108 subjects, operations were performed on 29 patients with 
locally advanced pancreatic ductal cancer, and the histological diagnosis was proven in these 
patients. The remaining patients were diagnosed on the basis of PET/CE-CT imaging findings and 
serum tumor marker values.  
PET/CE-CT imaging was conducted for relevant pancreatic tumor lesions to assess the 
usefulness of the maximum standardized uptake value (SUVmax) in differentiating benign and 
malignant pancreatic lesions. The SUVmax was the value obtained at 90 min after intravenous 
injection of fluorodeoxyglucose (FDG) in subjects with blood glucose levels of 200 mg/dL or less 
at the time of FDG administration. 
Differential diagnosis for malignant and benign pancreatic disorders by PET/CE-CT imaging was 
performed in 21 patients with intraductal papillary mucinous neoplasm (IPMN; 9 men and 12 
women; age, 47–78 years), 10 patients with endocrine tumors of the pancreas (2 men and 8 
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women; age, 42–78 years), and 10 patients with tumor-forming pancreatitis (chronic pancreatitis 
[CP] or autoimmune pancreatitis [AIP]; 8 men and 2 women; age, 40–79 years) in addition to the 
108 patients with invasive pancreatic ductal cancer. Among the 21 IPMN patients, 8 patients 
underwent operations, and the diagnosis of malignant tumors (intraductal papillary mucinous 
carcinoma [IPMC]) and benign tumors (intraductal papillary mucinous adenoma [IPMA]) was 
histologically proven in these patients. The remaining 13 patients were diagnosed with benign 
tumors (IPMA) based on the findings from imaging studies (PET/CE-CT, MRI, US), including 
branch type, lack of internal structures, and lack of FDG uptake. These patients are currently 
being observed by follow-up at more than 1 year after diagnosis. Ten patients with endocrine 
tumors of the pancreas were diagnosed based on the presence of hypervascular tumors with 
FDG accumulation upon PET/CE-CT imaging. Among these patients, 7 underwent operations, 
and biopsies were performed in the remaining 3 patients, resulting in histologically proven 
diagnoses for all 10 patients. Malignancy and benignancy were determined based on histological 
findings and by taking into account the presence or absence of metastatic lesions on the images. 
Chronic pancreatitis and AIP were diagnosed by PET/CE-CT imaging and serum levels of 
pancreatic enzymes and/or IgG4 according to the Diagnostic Criteria for Chronic Pancreatitis 
2002 [9] and the Diagnostic Criteria for Autoimmune Pancreatitis 2006 (Japan Pancreas Society) 
[10]. 
 
Classification of pancreatic cancer 
In this study, we employed the classification system for pancreatic cancer defined by the Japan 
Pancreas Society (JPS) [8]. According to the JPS classification system, the extent of invasive 
pancreatic ductal cancer was determined by taking into account local spread (T), lymph node 
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metastases (N), and distant metastases (M). The T category was defined through determination of 
the presence and extent of local invasion of the pancreas and adjacent structures. Within this 
category, 8 local extension factors were considered: the distal bile duct (CH), duodenum (DU), 
serosa (S), retropancreatic tissue (RP), portal venous system (PV), arterial system (A), 
extrapancreatic nerve plexus (PL), and other organs (OO). The N category (lymph node 
metastases) was divided into 4 categories (N0–N3) according to whether metastasis was present 
in lymph nodes with groups 1–3. The presence of distant metastatic lesions, including metastasis 
to distant organs, the peritoneum, and group 3 lymph nodes, were defined as M1. Based on the 
grading for T, N, and M categories, tumor stage was divided into 5 groups, as shown in Fig. 1. A 
detailed description of stage grouping by JPS guidelines is described in a previous report by Isaji 
et al. [8]. 
 
PET/CT imaging protocol 
All FDG-PET/CT studies were performed using an Aquiduo PET/CT scanner (Toshiba, Otawara, 
Japan), which is a hybrid PET and 16-MDCT scanner. Patients fasted for at least 4 h before the 
PET/CT examination. In all patients, blood glucose levels were checked before injection of the 
radiopharmaceutical. Intravenous injection of 3.0 MBq/kg body weight of FDG was followed by a 
10-mL normal saline flush. Patients rested for about 90 min, during which time they were asked to 
drink 500 mL of a Japanese tea containing 5 mL of oral contrast media (Gastrografin; Bayer 
Schering Pharma) prior to image acquisition and to void before being positioned supine on the 
scanner table. Noncontrast CT was performed first, from the vertex of the skull through the mid 
thigh at 80–200 mAs, 120 kVp, and 2.0-mm collimation. Images were reconstructed as 
contiguous 4-mm slices. PET was performed immediately after noncontrast CT without 
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repositioning the patient. PET images were obtained at 7–8 stations per patient, with an 
acquisition time of 2–3 min per station, from the skull vertex through the mid thigh. The 
noncontrast CT data were used for attenuation correction of PET emission images, which were 
coregistered with the noncontrast CT dataset. Then, dual phase contrast-enhanced CT was 
performed. Arterial phase CT images were obtained 35 sec after injection of 100 mL iopamidol 
(Iopamiron 300, Bayer Schering Pharma). Contrast material was injected at 3 mL/s using a 
powder injector (Dual Shot GV, Nemoto). Arterial phase images were obtained from the dome of 
the diaphragm to the iliac crest at 80–200 mAs, 120 kVp, and 1.0-mm collimation. Arterial phase 
images were reconstructed as contiguous 2-mm slices. Portal venous phase images were 
acquired after a delay of 90 sec from the vertex of the skull through the mid thigh at 80–200 mAs, 
120 kVp, and 2.0-mm collimation. Portal venous phase images were reconstructed as contiguous 
2-mm slices. 
PET/CT imaging using this protocol (PET/CE-CT) can cover all angles of the diagnosis, 
including diagnosis of existing tumors, qualitative diagnosis, local diagnosis, and metastasis 
detection.  
 
Evaluation of the extent of invasive pancreatic ductal cancer 
Operations were performed on 29 patients with locally advanced pancreatic ductal cancer 
(Stage IVa), and diagnoses were histologically proven in these patients. Postoperatively, findings 
from PET/CE-CT imaging of the pre-operative cancer were compared with the histological 
findings of the resected specimens in order to determine the diagnostic accuracy rate of 
PET/CE-CT imaging for the evaluation of the extent of cancer progression. The degree of 
pre-operative and postoperative cancer progression was determined according to the JPS 
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classification system [8]. In another 4 patients with invasive pancreatic ductal cancer, whose 
pre-operative stage was diagnosed as resectable IVa by PET/CE-CT, only metastatic tissue 
biopsies were performed since distant metastases were found after initiation of the surgical 
procedure (lymph node [N3], 2 cases; liver, 1 case; peritoneum, 1 case). Thus, N and M 
categories were examined in 31 patients with stage IVa after the addition of these 2 cases. We 
also compared the diagnostic accuracy rate of PET/CE-CT imaging with that of abdominal CE-CT 
imaging, which was extracted from the PET/CE-CT imaging, for evaluating cancer extent. 
We further evaluated the diagnostic accuracy rate of PET/CE-CT for M factor analysis in 65 
patients with stage IVb unresectable pancreatic cancer, since distant metastases are not normally 
found in stage IVa resectable pancreatic cancer, and compared it with that of CE-CT images, 
which were extracted from the PET/CE-CT images. In this analysis, the reference standard for the 
presence of distant metastases was based on multimodality images and follow-up observations 
since distant metastases were not histologically proven. 
To compare the diagnostic accuracy rates of PET/CE-CT and abdominal CE-CT in the context of 
evaluating T, N, and M factors, 2 radiologists were asked to analyze sections from these images 
independently, without knowledge of the results of the other imaging. If a disagreement occurred, 
a final decision was made after a discussion of the radiologists’ analyses. 
 
Assessment of treatment effects 
The effects of treatment were evaluated over time in 8 patients who had undergone 
chemotherapy or chemoradiotherapy for unresectable locally advanced pancreatic cancer, 
diagnosed using PET/CE-CT imaging (tumor diameter determined by CT and SUVmax determined 
by PET) and serum tumor marker levels (CA19-9). After determining the rate of increases and 
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decreases in tumor diameter, SUVmax values and CA19-9 levels were assessed, and correlations 
among these factors were examined. This analysis was conducted only on patients whose 
pancreatic cancer was locally confined during the ongoing treatment and was discontinued 
whenever distant metastasis occurred. At each evaluation of treatment effectiveness, the change 
rate of each variable was calculated and examined for correlations. Therefore, although 8 patients 
were analyzed, the number of analyzable events was 12, since multiple events occurred per case. 
 
Diagnosis of postoperative recurrence 
While pancreatic cancer often recurs soon after surgery, the anatomical positional relationship 
between various abdominal organs may be changed by surgery; therefore, an abdominal CE-CT 
scan alone is often insufficient for diagnosis of local recurrence, not to mention distant metastasis. 
In the present study, PET/CE-CT images were used to show postoperative recurrence in 11 
patients and a lack of postoperative recurrence of invasive pancreatic ductal cancer in 6 patients. 
Local recurrence was diagnosed by PET/CE-CT based on the findings of soft tissue-density mass 
with FDG accumulation, while soft tissue-density mass without FDG accumulation was diagnosed 
as a postoperative change. The diagnosis of local recurrence by abdominal CE-CT, on the other 
hand, requires not only the presence of soft tissue-density mass, but also the ability to compare 
the mass with the size with the previously measured mass. Thus, an increase in the size of the 
soft tissue-density mass was considered a local recurrence, while no increase and/or little 
increase in size was considered a lack of local recurrence. However, there is no standard criteria 
defining the increase in size that would constitute a local recurrence; thus, the diagnosis of local 
recurrence depends on the radiologist. In our cancer center, PET/CE-CT is usually conducted on 
patients in whom the serum levels of tumor markers are elevated during the follow-up period. To 
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determine the diagnostic accuracy rate of abdominal CE-CT for the evaluation of local recurrence, 
2 radiologists were asked to read only sections from abdominal CE-CT scans extracted from 
PET/CE-CT imaging independently, without knowledge of the results of other imaging findings. If 
a disagreement occurred, a final decision was made after discussion between the radiologists. 
Then, the diagnostic accuracy rate for local recurrence was compared between PET/CE-CT and 
abdominal CE-CT imaging. Although local recurrences were not histologically proven, they were 
confirmed by follow-up observations after the initial diagnosis by PET/CE-CT. As a result, the 
diagnostic accuracy rate of PET/CE-CT was 100%. 
 
Statistical analysis 
Differences between the SUVmax values in various pancreatic disorders with tumorous lesions 
were evaluated using the t-test. Differences in the diagnostic accuracy rates of the tested imaging 
modalities (PET/CE-CT and abdominal CE-CT) were evaluated using the Cochran Q test. 
Relationships between changes in tumor size, SUVmax values, and serum CA-19-9 levels during 
treatment were evaluated using linear regression analysis. A p-value of less than 0.05 was 
considered statistically significant. 
 
Results 
1. Differential diagnosis of the malignancy and benignancy of pancreatic lesions by PET/CE-CT 
imaging 
Fig. 2 shows the SUVmax of various pancreatic tumor diseases. The SUVmax (mean ± SD) of 
invasive pancreatic ductal cancer was 6.14 ± 3.51 in stages I–III, 6.28 ± 2.91 in stage IVa, and 
7.22 ± 2.65 in stage IVb; thus, the values for different stages were not significantly different. 
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However, the SUVmax of invasive pancreatic ductal cancer tended to be higher than those of other 
pancreatic tumor diseases, excluding benign pancreatic endocrine tumors. In the case of IPMN, 
the SUVmax values (mean ± SD) were 3.09 ± 1.53 for IPMC (n = 5) and 1.59 ± 0.52 for IPMA (n = 
16). The SUVmax of IPMC was significantly higher than that of IPMA (P < 0.005). In the case of 
pancreatic endocrine tumors, the SUVmax values (mean ± SD) were 27.4 ± 18.2 (n = 3) in benign 
cases and 4.21 ± 2.56 (n = 7) in malignant cases; thus, the SUV was markedly higher in benign 
cases. Among 3 cases of benign endocrine tumors, 2 cases exhibited extremely high SUVmax 
values, 33.5 and 46.1, and the histological diagnosis for these cases was well-differentiated 
endocrine tumors with uncertain behavior according to the WHO classification of endocrine 
tumors published in 2004 [11]. These 2 cases have been followed up for more than 3 years, and 
recurrence was not noted until August 2011. In tumor-forming chronic pancreatitis and 
tumor-forming AIP, SUVmax values (mean ± SD) were 2.19 ± 0.48 (n = 5) and 4.76 ± 1.64 (n = 5), 
respectively; therefore, the SUVmax of AIP was significantly higher than that of chronic pancreatitis 
(P < 0.01).  
 
2. Diagnostic accuracy rate of PET/CE-CT imaging for determining the extent of invasive 
pancreatic ductal cancer 
The diagnostic accuracy rate of PET/CE-CT for T, N, and M factor in patients with stage IVa 
resectable pancreatic cancer is shown in Table 1. 
With respect to the T factor, the diagnostic accuracy rate of PET/CE-CT imaging for tumor size 
(Ts), serosa(S), and retropancreatic tissue(RP) was below 80%, while it was greater than 80% for 
distal bile duct(CH), duodenum(DU), portal vein system(PV), arterial system(A), extrapancreatic 
nerve plexus(PL) and other organ(OO). Among these factors in the T category, A, PV, and PL are 
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important to determine whether the locally advanced pancreatic cancer (stage IVa) is resectable. 
The diagnostic accuracy rates of A, PV, and PL were 97%, 86%, and 83%, respectively. 
Evaluation of the T factor by PET/CE-CT was based on the findings of the CE-CT images; 
therefore, the diagnostic accuracy rate of PET/CE-CT for the T factor was identical to that of 
abdominal CE-CT (data not shown). 
Abdominal CE-CT imaging was used to determine the extent of N factor based on the shape and 
size of lymph nodes, while FDG uptake was used as an additional evaluation element in 
PET/CE-CT imaging (Fig. 3). The accuracy rate of PET/CE-CT for the N factor was 42% (Table 
1-A), while that of abdominal CE-CT was 35% in 31 patients with stage IVa resectable pancreatic 
cancer (data not shown). The breakdown of differentially diagnosed N factor characteristics as 
measured by PET/CE-CT and histological examination (n = 18) is shown in Table 1-B. Among 
these N factor diagnoses, overestimation and underestimation of the extent of N factor 
characteristics by PET/CE-CT were observed in 6 and 12 patients, respectively. In the 6 cases of 
overestimation, 4 were determined to be stage IVb unresectable cases solely based on the 
pre-operative evaluation of N2 or N3 by PET/CE-CT. In the 12 cases of underestimation, on the 
other hand, 9 with peripancreatic lymph node metastasis in the resected specimen, which is 
histologically diagnosed as N1, were included. 
With respect to the M factor, the diagnostic accuracy rate of PET/CE-CT imaging was 94% in 31 
patients with stage IVa resectable pancreatic cancer (Table 1-A). Two metastatic cases, 1 with 
metastasis to the surface of the liver and the other with miliary nodules of peritoneal dissemination, 
were not detected by the pre-operative PET/CE-CT. We also evaluated the diagnostic accuracy 
rate of PET/CE-CT for M factor characteristics in 65 patients with stage IVb unresectable 
pancreatic cancer (Table 2). Lymph node metastasis (N3), hepatic metastasis, and peritoneal 
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dissemination, which are often observed as distant metastasis of pancreatic cancer, were 
detected in 51%, 55%, and 53% of patients by PET/CE-CT and 45%, 53%, and 31% of cases by 
abdominal CE-CT, respectively. The detection rates of abdominal CE-CT for lymph node 
metastasis (N3) and peritoneal dissemination were significantly lower than that of PET/CE-CT, 
although the detection rate of hepatic metastasis was similar between the 2 methods. Lung and 
bone metastasis have rarely been detected by abdominal CE-CT because this type of imaging 
scans only a segmental area. PET/CE-CT imaging, on the other hand, scans the whole body, 
resulting in higher detection rates of lung and bone metastases (Table 2). 
 
3. Assessment of treatment effects by PET/CE-CT imaging 
Unresectable pancreatic cancer is treated with chemotherapy or chemoradiotherapy, and the 
effectiveness of treatment is assessed according to RECIST guidelines [12] by determining the 
longest diameter of the measurable lesion, which is usually measured using abdominal CE-CT, 
and levels of serum tumor marker.  
We determined the increase/decrease ratios of tumor size, CA19-9 levels, and SUVmax in the 
progressive disease (PD) and partial response (PR) groups. In contrast to small changes in tumor 
size, the changes in CA19-9 levels and SUVmax values were larger, and the patterns of changes in 
these indicators were similar (Fig. 4-a). Among these 3 indicators, a significant positive correlation 
was found between SUVmax and CA19-9 levels (P < 0.0001) and between SUVmax and tumor size 
(P < 0.05), but no significant correlation was found between CA19-9 levels and tumor size (Fig. 
4-b). 
 
4. Diagnosis of postoperative recurrence 
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In patients with pancreatic cancer, recurrence is frequently observed shortly after the operation 
[13]; thus, diagnosis of recurrence is crucial for starting an appropriate treatment. Abdominal 
CE-CT is generally used for this diagnosis; however, in some cases, local recurrence may be 
difficult to detect because of postoperative alterations in the anatomical positions of visceral 
organs [14, 15]. Therefore, we compared the rates of postoperative local recurrences diagnosed 
by abdominal CE-CT and PET/CE-CT imaging. Abdominal CE-CT detected 7 out of the 11 cases 
diagnosed by PET/CE-CT imaging, and in 6 cases diagnosed as not having local recurrence by 
PET/CE-CT imaging, 5 cases were diagnosed correctly by abdominal CE-CT (Table 3). Typical 
findings from imaging of local recurrences by PET/CE-CT are shown in Fig. 5.  
 
Discussion 
Pre-operative evaluation of the extent of pancreatic cancer is important in deciding treatment 
options, and abdominal CE-CT is usually used for this purpose. In the present study, we 
determined the diagnostic accuracy rate of PET/CE-CT in evaluating the extent of pancreatic 
cancer, and compared it to that of abdominal CE-CT. The accuracy rate for diagnosing the T factor, 
which includes an evaluation of local spread or invasion into the area surrounding the pancreas, 
was less than 80% for tumor size(Ts), serosa(S), and retropancreatic tissue(RP), and greater than 
80% for the distal bile duct(CH), duodenum(DU), portal vein system(PV), arterial system(A), 
extrapancreatic nerve plexus(PL) and other organ(OO). Among these factors, PV, A, and PL are 
important in deciding whether the tumors are resectable or not, and the accuracy rates of 
PET/CE-CT for these factors (PV, 86%; A, 97%; and PL, 87%) were satisfactory. The accuracy 
rate of abdominal CE-CT imaging for the T factor was identical to that of PET/CE-CT imaging, 
since the CE-CT portion is the main evaluation tool for T factor analysis even on PET/CE-CT 
 15 
 
imaging. With respect to the N factor, Higashi et al. [16] reported that the diagnostic accuracy rate 
assessed by CT images was not satisfactory. Zimny et al. [17] reported a low accuracy rate for 
FDG-PET in evaluation of the N factor as well. In the present study, the diagnostic accuracy rate 
of PET/CE-CT for the N factor was 42%, despite the fact that the diagnosis was based on both CT 
images of the size and shape of lymph nodes and FDG uptake on PET, while the diagnostic 
accuracy rate of abdominal CE-CT was even lower (35%). The extent of the N factor was 
differentially diagnosed with PET/CE-CT and histological examination in 18 cases; however, of 
these 18 cases, 9 cases of Group 1-lymph node metastasis were diagnosed as N0 on 
PET/CE-CT but as N1 by histological examination. These lymph nodes were attached to the 
resected specimens; therefore, detection of such lymph node metastasis by imaging seems 
impossible because of their small size and/or their merging with pancreatic tumors. If these 9 
cases were excluded from our calculation of the diagnostic accuracy rate, the accuracy rate of 
PET/CE-CT for the N factor would be 13/22 (59%), although even this level is low. These results 
indicate that PET/CE-CT imaging is not very useful for assessing the N factor, which is consistent 
with previous reports [16, 17]. On the other hand, PET/CE-CT is very useful in evaluation of the M 
factor, as indicated by the high accuracy rate of PET/CE-CT within this context. In fact, the 
diagnostic accuracy rate of PET/CE-CT for the M factor was 94% in 31 patients with stage IVa 
resectable cancers. Furthermore, in 65 patients with stage IVb unresectable cancers, the 
detection rates of PET/CE-CT for metastases to the lymph nodes (N3), liver, peritoneum, lung, 
and bone were 51%, 55%, 53%, 18%, and 24%, respectively. These detection rates for distant 
lymph node (N3) and peritoneum metastases were significantly higher for PET/CE-CT imaging 
than for abdominal CE-CT imaging. The detection rates of PET/CE-CT for lung and bone 
metastases were also higher than those of abdominal CE-CT imaging. However, such differences 
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were attributed to the nature of PET/CE-CT scans (whole body imaging) and abdominal CE-CT 
scans (imaging of only a segmental area). Therefore, in the pre-operative evaluation of the extent 
of pancreatic cancer, which is important for deciding treatment options, our present results 
suggest that PET/CE-CT is a useful tool for assessing T and M factors, but is not very useful for 
assessing the N factor. This is consistent with a report by Strobel et al. [18], in which PET/CE-CT 
was found to be superior to PET imaging alone in assessing the respectability of pancreatic 
cancer. 
When PET was first developed, many published reports stated that the SUVmax could be useful 
for differentially diagnosing malignancies and benignancies [16, 19]. Nishiyama et al. [20] and 
Nakamoto et al. [21] reported that a malignancy could be differentiated from a benignancy in 
pancreatic disorders based on the SUVmax to delayed scan ratio. However, as described in the 
present study, the SUVmax of malignant pancreatic tumors overlapped with that of benign 
pancreatic diseases, suggesting that distinguishing between benign and malignant cases through 
SUVmax-based diagnosis is difficult. Extremely high SUVmax values were observed in 2 cases of 
benign pancreatic endocrine tumor in the present study. The SUVmax varies according to the 
several factors, including blood glucose levels, Glut 1 expression, glucose-6-phosphatase 
expression, and tumor heterogeneity, etc. [16]. In a previous study, high SUVmax values were 
found in tumors with high Glut 1 expression [22]. In our study, extremely high SUVmax values were 
observed in 2 cases of benign endocrine tumors, and these high values may be attributed to high 
Glut 1 expression in these tumors; however, Glut 1 expression was not examined histologically. In 
order to differentiate between benignancy and malignancy of pancreatic tumor lesions by 
PET/CE-CT imaging, we first assessed the invasion of the tumors into surrounding 
organs/vessels and other malignancy-indicating signs by analysis of the CE-CT portion of 
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PET/CE-CT imaging and then diagnosed the case by referring to the FDG uptake data (SUVmax) 
by analysis of the PET portion. We did not use SUVmax values for differentiating between 
benignancy and malignancy. So, what is the meaning of SUVmax in the clinical management of 
pancreatic cancer? In the present study, we examined correlations between the SUVmax, tumor 
size, and tumor marker (CA19-9) levels in unresectable locally advanced pancreatic cancer under 
treatment. During the course of treatment, SUVmax and CA19-9 levels showed substantial positive 
correlations in the change rate, while SUVmax and tumor size showed significant, although slight, 
positive correlations. However, no significant correlation was found between tumor marker levels 
and tumor size. Treatment effects on solid tumors were assessed by determining tumor size by 
imaging according to the RECIST criteria [12] and by the levels of serum tumor markers. In 
pancreatic cancer, however, changes in tumor size do not necessarily reflect treatment effects, 
since pancreatic cancers contain a variety of interstitial components. Thus, we have frequently 
experienced discrepancies between changes in tumor size and tumor marker levels in assessing 
the effects of treatment, which makes it difficult to determine the effects of treatment in these 
cases. Identification of an additional indicator would help in determining the effects of treatment 
on pancreatic cancer progression/regression. In the present study, we demonstrated that the 
SUVmax measured by PET proved useful in this regard. Similarly, Yoshioka et al. [23] reported that 
the SUVmax was useful to monitor the effects of treatment on pancreatic cancers. These findings, 
together with those in the present study, suggest that the SUVmax is a useful indicator for the 
effects of treatment on pancreatic cancer. The addition of the SUVmax to the existing indicators 
(tumor size and markers) is expected to reduce the difficulty of assessing the effects of treatment 
on pancreatic cancer progression.    
Since either invasion into the surrounding regions or distant metastasis is often already involved 
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at the time of pancreatic cancer diagnosis, less than 20% of cases are treated surgically [24]. 
Even when surgery is employed, recurrence usually occurs very soon thereafter [13]. Therefore, 
cautious observation is required after surgery. In general, abdominal CE-CT is conducted every 
3–6 months for postoperative monitoring. Local, hepatic, and peritoneal recurrences are 
frequently observed postoperatively. Abdominal CE-CT can be used to diagnose hepatic 
recurrence, but it is sometimes difficult to detect local or peritoneal recurrences due to 
postoperative changes in the anatomical positions of organs [15, 17]. Ruf et al. [25] showed that 
FDG-PET is superior to CT/MRI in the detection of local recurrences of pancreatic cancers. In the 
present study, we demonstrated that the diagnostic accuracy of PET/CE-CT is superior to 
abdominal CE-CT in predicting the postoperative local recurrence of pancreatic cancer. 
Considering the postoperative changes in the anatomical positions of abdominal organs, 
PET/CE-CT imaging, which employs both contrast-enhanced CT and PET functions, is 
recommended for postoperative monitoring. 
 
Conclusion 
In the present study, we demonstrated that PET/CE-CT imaging can provide useful information 
in the clinical management of pancreatic cancer. We recommend PET/CE-CT imaging as the first 
choice examination for suspected pancreatic cancer, staging, assessment of treatment 
effectiveness, and confirmation of suspected recurrence. 
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Figure Legends 
Figure 1: Stage grouping of pancreatic cancers according to JPS guidelines [8]. 
Stages of pancreatic cancer are grouped into 5 categories according to the cancer extent 
based on the grading of T, N, and M factors. 
Figure 2: SUVmax of different pancreatic tumor lesions. 
Ninety minutes after FDG infusion in various pancreatic tumor cases, PET/CE-CT scans 
were conducted to determine the SUVmax. Patients with blood glucose levels of 200 mg/dL 
or less at the time of FDG infusion were evaluated.  
Figure 3: PET/CE-CT findings of a typical case (86-year old woman) with lymph node metastasis.  
The CE-CT image shows #16b1 lymph node swelling (10.5 × 5.0 mm, flat shape); 
however, lymph node metastasis was ruled out based on the size and shape of the 
swelling as determined by CT (A). The PET/CT image, on the other hand, shows 
abnormal FDG uptake (SUVmax, 2.61) corresponding to this lymph node (B), suggesting 
lymph node metastasis. Histological examination of the surgical specimen proved the 
involvement of lymph node lesions.  
Figure 4: Monitoring treatment effectiveness in invasive pancreatic ductal cancer by PET/CE-CT. 
Chemotherapy or chemoradiotherapy was conducted in 8 patients with unresectable 
locally advanced pancreatic cancer. PET/CE-CT imaging (SUVmax by PET and tumor size 
by CE-CT) and levels of serum tumor markers (CA19-9) were used to assess the effects 
of treatment over time. Only tumors that were found to be locally confined during 
treatment were analyzed. Cases in which distant metastasis occurred were excluded from 
analysis.  
A. Changes in tumor size, CA19-9, and SUVmax during treatment.  
Compared to the baseline values (100%), the values at PR or PD are indicated by the % 
decrease or increase. 
B. Correlations between the rate of change in tumor size, CA19-9, and SUVmax during 
treatment. (NS: not significant) 
Figure 5: PET/CE-CT findings of 2 typical cases, 1 with “local recurrence” and the other with “no 
local recurrence,” are shown.    
A. A 46-year-old man with no local recurrence (false-positive by CE-CT and true-negative 
by PET/CE-CT).  
The CE-CT image, which was performed 17 months after surgery, showed a soft-tissue 
density mass, which did not rule out local recurrence (left upper panel, arrow). However, 
the PET/CT image did not show FDG uptake corresponding to this mass, suggesting no 
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local recurrence (left lower panel, arrow). A follow-up PET/CE-CT image, which was 
performed 8 months after the initial examination, revealed no increase in the size and 
FDG uptake of the mass (right panel, arrow), indicating that the initial diagnosis of no local 
recurrence by PET/CE-CT was correct.  
B. A 59-year-old man with local recurrence (true-positive by CE-CT and PET/CE-CT).  
The CE-CT image, which was performed 3 months after surgery, showed a soft-tissue 
density mass, which did not rule out local recurrence (left upper panel, arrow). The 
PET/CT image shows abnormal FDG uptake (SUVmax, 4.73) corresponding to this mass, 
suggesting local recurrence (left lower panel, arrow). A follow-up PET/CE-CT image, 
which was performed 3 months after the initial examination, revealed an increase in the 
size and FDG uptake (SUVmax, 6.99) of the mass (right panel, arrow), indicating that the 
initial diagnosis of local recurrence by PET/CE-CT was correct. 
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PET/CE-CT
T factor: Ts 14/28 ( 50%)
CH 24/29 ( 83%)
DU 26/29 ( 90%)
S 22/29 ( 76%)
RP 19/29 ( 66%)
PV 25/29 ( 86%)
A 28/29 ( 97%)
PL 24/29 ( 83%)
OO 29/29 (100%)
N factor: 13/31 ( 42%) 
M factor: 29/31 ( 94%) 
 
 
Extent of N factor Number 
of cases
 
(n=18) 
PET/CT 
imaging 
histological 
examination 
N3, N2  → N1 4
N1   → N0 2
N0   → N1 9
N0    → N2 1 
N0    → N3 2 
A: Diagnostic accuracy rate of PET/CE-CT imaging in determining the extent of 
cancer in 31 patients with pre-operative stage IVa resectable pancreatic cancer. 
Table 1: 
The extent of cancer was determined with regard to local spread (T), lymph node metastasis (N),
and distant metastasis (M) according to the classification guidelines for pancreatic carcinomas 
published by the Japan Pancreas Society (8). Pre-operative cancer extent diagnosed by 
PET/CE-CT imaging and histological examination of resected specimens were compared among 
29 patients with stage IVa resectable pancreatic cancer to calculate the diagnostic accuracy rate 
of PET/CE-CT imaging. Ts was not assessable in 1 resected specimen; therefore, Ts was 
determined in 28 specimens. Distant metastases were histologically proven in 4 more cases (2 
lymph node [N3], 1 hepatic, and 1 peritoneal metastasis), in addition to 29 patients with stage IVa 
resectable pancreatic cancer, in whom only tissue biopsies were performed after initiation of the 
surgical procedure. These 4 cases were included in N and M factor evaluation; therefore, N and M 
factors were histologically determined in 31 specimens. 
B: Breakdown of the differently diagnosed extent of the N factor with PET/CE-CT 
imaging and histological examination in 18 of 31 patients with pre-operative stage 
IVa resectable pancreatic cancer. 
 
A. B.
Ts, tumor size; CH, distal bile duct; DU, duodenum; S, serosa; RP, retropancreatic tissue; PV, 
portal vein system; A, arterial system; PL, extrapancreatic nerve plexus; OO, other organ. 
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PET/CE-CT abdominal  CE-CT 
Lymph node (N3) 33 (51%) 29 (45%) †  
Liver 36 (55%) 35 (53%) 
Peritoneum 35 (53%) 20 (31%) ‡  
Lung 12 (18%) 5 ( 8%) ‡  
Bone 16 (24%) 3 ( 5%) ‡  
 
 
PET/CE-CT was conducted at the time of diagnosis in 65 patients. The portions 
that correspond to the abdominal CE-CT were extracted from the PET/CE-CT 
images and reconstructed. Then, 2 radiologists assessed the extent of M factor 
characteristics on these extracted images. If a disagreement occurred, a final 
decision was made after discussion between the radiologists. 
 
†p < 0.05 vs. PET/CE-CT 
‡p < 0.01 vs. PET/CE-CT 
Table 2: Difference between PET/CE-CT and abdonimal CE-CT in the 
diagnosis of the extent of M factor progression in 65 patients with 
stage IVb unresectable pancreatic cancer. 
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 PET/CT 
recurrence
 (n = 11)  
no recurrence 
(n = 6)  
CT 
recurrence  7  1  
No recurrence 4  5  
Accuracy rate 63%      83%  
Above are 11 cases diagnosed as “local recurrence” and 6 cases diagnosed 
as “no recurrence” by PET/CE-CT imaging during the postoperative 
monitoring period. The portion that corresponds to the abdominal CE-CT was 
extracted from PET/CE-CT images and reconstructed. Local recurrence was 
diagnosed by PET/CE-CT based on the findings of soft tissue-density mass 
with FDG accumulation, while soft tissue-density mass without FDG 
accumulation was diagnosed as a postoperative change. The diagnosis of 
local recurrence by abdominal CE-CT, on the other hand, required not only 
the presence of soft tissue-density mass, but also the comparison of the 
current tumor size with the previous measure of tumor size. Two radiologists 
assessed local recurrence on these extracted images. If a disagreement 
occurred, a final decision was made after discussion between the 
radiologists.  
Table 3: PET/CE-CT vs. abdominal CE-CT for the diagnosis of  
postoperative local recurrence. 
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